CytRx Highlights Orphazyme's Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
Stock Information for LadRx
Loading
Please wait while we load your information from QuoteMedia.
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.